CRMD
$6.46
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Recent News
CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink
CorMedix (NASDAQ:CRMD) Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has undergone a significant shift over the last year, moving from what he described as a “single product company” to a diversified specialty pharmaceutical busine
CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference
CorMedix (NASDAQ:CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company’s focus on expanding its pipeline while integrating the recently acquired Melinta Therapeutics assets and navigating evolving reimbursement dynamics for its catheter lock solution De
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations
Key recent performance context CorMedix (CRMD) has drawn investor attention after a weak run in the stock, with the share price showing negative returns over the past week, month, past 3 months and year to date. See our latest analysis for CorMedix. At a share price of US$6.30, CorMedix has seen momentum fade recently, with a 1 day share price return of 11.52% decline adding to a 30 day share price return of 22.41% decline. Its 3 year total shareholder return of 67.55% contrasts with a 1 year...
CorMedix Inc. Q4 2025 Earnings Call Summary
Moby summary of CorMedix Inc.'s Q4 2025 earnings call
CorMedix Buyback And REZZAYO Data Shape Valuation And Risk Profile
CorMedix (NasdaqGM:CRMD) has authorized a $75 million share repurchase program following a recent move into profitability. The company is progressing with the integration of Melinta Therapeutics’ portfolio into its operations. Late stage Phase 3 clinical data for its REZZAYO antifungal drug are expected, which could be a key event for the pipeline. For investors watching CorMedix at a share price of $6.30, the new buyback plan, profitability, and portfolio integration arrive after a mixed...